Abstract
In 1948, Conley and coworkers (2) observed that patients with thrombocytopenia had an increased sensitivity to heparin and suggested that platelets could counteract the anticoagulant effect of heparin. This observation was subsequently confirmed by other workers, who demonstrated that platelets contain a heparin-neutralizing substance (21, 42) referred to as Platelet Factor-4 (PF-4) (10); in 1957, Deutsch and coworkers (11) provided evidence that PF-4 is a real platelet and not a plasma factor adsorbed on the platelet surface. This factor was also shown to be different from the platelet thromboplastic factor (platelet factor-3) (43). Little is known, however, about the mechanism by which heparin is neutralized by platelets. The existence of weak “heparin-platelet” complexes has been suggested (31, 38), but direct evidence for such complexes still is lacking. Antiheparin activity of platelets was shown to be easily extracted from platelet homogenates with saline or buffer and to be insoluble in lipid solvents (11, 43).
Keywords
- Platelet Aggregation
- Idiopathic Thrombocytopenic Purpura
- Platelet Factor
- Release Reaction
- Aspirin Ingestion
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Supported in part by grant n. 1216 of the Fonds voor Wetenschappelijk Geneeskundig Onderzoek, Belgium.
On leave of absence from the Laboratory of Blood Coagulation (Prof. B. Bizzi), Department of Internal Medicine (Prof.R. Breda) Università Cattolica, Roma, Italy. Fellow of the Ministero della Pubblica Istruzione of Italy.
On leave of absence from the Department of Clinical Chemistry (Dr. A. Wolanska), Institute of Tuberculosis, Warsaw, Poland. Fellow of the Belgian Cultural Exchange Program.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Brown J. H., Mackey H. K., Riggilo D. A., A novel in vitro assay for antiinflammatory agents based on stabilization of erythrocytes. Proc. Soc. Exptl. Biol. Med., 125, 837, 1967.
Cowley C. L., Hartmann R. C., Lalley J. S., The relationship of heparin activity to platelet concentration Proc. Soc. Exptl. Biol. Med., 69, 284, 1948.
Day H. J., Stormorken K., Holmsen H., Subcellular localization of platelet factor 3 and platelet factor 4. Abstracts XII Congress Intern. Soc. Hemat., New York p. 172, 19
De Gaetano G., Discussion in: Acta Med. Scand., 1971, suppl. 525, p. 121.
De Gaetano G., Vermylen J., Verstraete M., Platelet aggregation by a specific human immunoglobulin preparation. Thromb. Diatli. haemorrh., 24, 419, 1970
De Gaetano G., Vermylen J., Verstraete M., Platelet aggregation by Thrombofax. Acta Univ. Carolinae Med., 1972, in press.
De Gaetano G., Vermylen J., Verstraete M., Platelet factor 3, I. Properties and clinical significance. This volume.
Deutsch E., Kain W. Studies on platelet factor 4, In: Henry Ford Hospital Intern. Symposium “Blood Platelets” 1960, p. 337.
Deutsch E., Lechner K., Platelet clotting factors. In “Biochemistry of Blood Platelets” edit, by Kowalski E. and Niewarowski S. Academic Press, London and New York, 1967, p. 23
Deutsch E., Johnson S. A., Seegers VI. H., Differentiation of certain platelet factors related to blood coagulation. Circ. Res., 3, 110, 1955.
Deutsch E., Wawersicii E., Franks G., Uber das Vorkommen eines Antiheparinfaktors in Thrombozyten und Geweben. I. Mitteilung Antiheparinaktivität der Thrombozyten. Thromb. Diath. haemorrh., 1, 3, 1957.
Donati M. B., Pales Terchlebowczyk M., De Gaetaito G., Vermylen J., Platelet factor 4. II. Methods of study This volume.
Eiber H. B., Danishefsky I., Heparin in blood. Proc. Soc. Exptl. Biol. Med., 94, 801, 1957.
Farbiszewski R., Lipinski B., Niewiarowski S., Poplawski A., Hypercoagulability and thrombocytopenia after platelet factor 4 infusion into rabbits. Experientia, 24, 578, 1968.
Farbiszewski R., Loewiarowski S., Worowski K., Lipinski B., Release of platelet factor 4 in vivo during intravascular coagulation and in thrombotic states. Thromb. Diath. haemorrh., 19, 578, 1968.
Harada K., Zucker M. B., Simultaneous development of platelet factor 4 activity and release of 14c-serotonin. Thromb. Diath. haemorrh., 25, 41, 1971
Holger-Madseit T., Reduction of heparin activity by plasma globulin in patients with increasing heparin resistance. Acta heamat., 27, 157, 1962.
Holmsm H., Day H. J., Storkmorken H., The platelet release reaction. Scand. J. Haemat., suppl. 8, 1969.
Jaques L. B., Momhouse F. C., Stewart M. A method for determination of heparin blood. J. Physiol., 109, 41, 1949.
Jürgens R., Die Blutplättchen und ihre Bedeutung für Blutungsneigung und Thrombusbildung. Dtsch. med. Wschr., 77, 1265, 1952.
Kubisz P., Sultan Y., Delobel J., Caen J., Mesure de la libération du facteur plaquettaire 4 (FP4) dans thrombopathies constitutionelles et acquises. Rev. Europ. Etudes Clin. Biol., 15, 698, 1970.
Lipihski B., Worowski K., Detection of soluble fibrin monomer complexes in human plasma by means of protamine sulphate test. Thromb. Diath. haemorrh., 20, 44, 1968.
Lipinski B., Worowski K., Jeljaszewicz J., Niewiarowski S., Rejniak L., Participation of soluble fibrin monomer complexes and platelet factor 4 in the generalized Schwartzman reaction. Thromb. Diath. haemorrh., 20, 285, 1968.
Louis J., Salmon J., Etude du syndrome de coagulation intravasculaire secondaire aux réactions anaphylactiques du lapin. Rôle du facteur 4 plaquettaire. Comptes rendus des séances de la Société de Biologie, 163, 2778, 1969.
Luscher E. F., Die Biochemie der Gerinnungsfaktoren der Thrombozyten. Fourth International Congress of Biochemistry Vienna, Pergamon Press, 1958, p. 75.
Marr J., Barboriak J. J., Johnson S. A., Relationship of appearance of adenosine diphosphate, fibrin formation and platelet aggregation in the haemostatic plug in vivo. Nature, 205, 259, 1965.
Niewiarowski S., Farbiszewski R., Poplawski A., Neutralization of antithrombin VI (fibrinogen degradation products) with platelet antiheparin factor (platelet factor 4) Thromb. Diath. haemorrh., 14, 490, 1965.
Niewiarowski S., Lipinski B., Farbiszewski R., Poplawski A., The release of platelet factor 4 during platelet aggregation and the possible significance of this reaction in hemostasis. Experientia, 24, 343, 1968.
Niewiarowski S. Poplawski A., Lipinski B., Farbiszewski R., The release of platelet clotting factors during aggregation and viscous metamorphosis. Exp. Biol. Med., 3, 121, 1968.
Niewiarowski S., Thomas D. P., Platelet factor 4 and adenosine diphosphate release during human platelet aggregation. Nature, 222, 1269, 1969.
Nilsson I. M., Wmckert A., Demonstration of a heparin-like anticoagulant in normal blood. I. Human blood. Acta Med. Scand., suppl. 150, 297, 1955.
O’Brien J. R., Effect of salicylates on human platelets. Lancet, 1, 779, 1968.
O’brien J. R., Finch W., Clark E., Platelet-bound and soluble platelet factor 4: effects of aggregating agents, of aggregation, and of aspirin. Proc. Soc. Exptl. Biol. Med., 134, 1128, 1970.
Pepper D. S., Moore S., Cash J. D., Preliminary studies on the isolation and characterization of human platelet anti-heparin activity (platelet factor 4). Abstract 2nd Congress International Society or Thrombosis and Haemostasis, Oslo, 244, 1971.
Poplawski A., Hiwiarowski S., Dissociation of platelet antiheparin factor (platelet factor 4) and lipoprotein lipase inhibitor. Biochim. Biophys. Acta, 90, 403, 1964.
Poplawski A., Prokopowicz J., Hewiarowski S., Antiheparin activity in subcellular fraction of human granulocytes. Thromb. Diath. haemorrh., 21, 170, 1969.
Rapaport S. I., Ames S. B., Antiheparin activity of erythrocyte hemolysate. Proc. Soc. Exptl. Biol. Med., 95, 158, 1957.
Rapaport S. I., Ames S. B., Clotting factor assays on plasma from patients receiving intra-muscular or subcutaneous heparin. Amer. J. Med. Scien., 234, 678, 1957.
Solum N. O., Platelet aggregation during fibrin polymerization. Scand. J. clin. Lab. Invest., 18, 577, 1966.
Stewart G. J., Niewiarowski S., Aggregation of fibrinogen and its degradation products by basic proteins. An electron microscope study. Thromb. Diath. haemorrh., 25, 566, 1971.
Tamka K., Ilzuka Y., Suppression of enzyme release from isolated rat liver lysosomes by non-steroidal anti-inflammatory drugs. Biochem. Pharmacol., 17, 2023, 1960.
Vait Creveld S., Paulssen M. M., Significance of clotting factors in blood platelets in normal and pathological conditions. Lancet, 2, 242, 1951.
Vaedeedriessche R., Separation of the thromboplastic activity and the heparin-neutralizing auction of thrombocytes. Acta Med. Scand., 165, 217, 1959.
Vermylm J., Dotrsmont G., Donati M. B., De Gaetauo G., Michielsen P., Pharmacological modification of urinary excretion of fibrinogenlike material in glomerulonephritis. Scand. J. Haemat., suppl. 13, p. 365, 1971.
Verstraete M., Platelet factors. Thromb. Diath. haernorrh., suppl. 20, 397, 1966.
Wegrzynonicz Z., Personal communication.
Youssef A., Barkhan P., Release of platelet factor 4 by adenosine diphosphate and other platelet aggregating agents. Brit. Med. J., 1, 746, 1968.
Youssef A. H., Barkhan P., Inhibition by aspirin of release of antiheparin activity from human platelets. Brit. Med. J., 3, 394, 1969.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1972 Plenum Press, New York
About this paper
Cite this paper
Donati, M.B., Palester-Chlebowczyk, M., de Gaetano, G., Vermylen, J. (1972). Platelet Factor-4 Properties and Clinical Significance. In: Mannucci, P.M., Gorini, S. (eds) Platelet Function and Thrombosis. Advances in Experimental Medicine and Biology, vol 34. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-3231-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-4684-3231-2_10
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4684-3233-6
Online ISBN: 978-1-4684-3231-2
eBook Packages: Springer Book Archive